We just finished anther trial—a phase II trial of Recentin (an oral pan-VEGF receptor tyrosine kinase inhibitor, made by AstraZeneca and formerly called AZD2171) in patients with recurrent glioblastoma who have an expected survival of six months.
This trial, led by my colleague and collaborator Dr. Tracy Batchelor, the executive director of the neuro-oncology center at MGH, showed that normalization begins within one to two days of drug administration, is reversible, lasts at least 28 days, and can be detected with magnetic resonance imaging (MRI). This trial also allowed us to identify some blood biomarkers that correlate with tumor progression and escape from normalization.
This work was published in the January 2007 issue of Cancer Cell. This trial has formed the basis of a randomized phase III clinical trial in recurrent glioblastoma patients that will open at the MGH and other Harvard teaching hospitals in 2007.